Biological activities of ecalectin: A novel eosinophil-activating factor

Ryoji Matsumoto, Mitsuomi Hirashima, Hirohito Kita, Gerald J. Gleich

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Ecalectin, produced by Ag-stimulated T lymphocytes, is a potent eosinophil-specific chemoattractant in vitro as well as in vivo and thus is implicated in allergic responses. Ecalectin differs structurally from other known eosinophil chemoattractants (ECAs); ecalectin belongs to the galectin family defined by their affinity for β-galactosides and by their conserved carbohydrate recognition domains. These characteristic features suggest that ecalectin has unique activities associated with allergic inflammation besides ECA activity. Conversely, ecalectin may mediate ECA activity by binding to a receptor of a known ECA via affinity for the β-galactosides present on this receptor. In this study, we have tested whether ecalectin mediates ECA activity by binding to a receptor of a known ECA, and we have assessed its effects on eosinophils. Ecalectin did not mediate ECA activity by binding to the IL-5R or to CCR3. Also, the ECA activity of ecalectin was mainly chemokinetic. In addition, ecalectin induced concentration-dependent eosinophil aggregation, a marker for eosinophil activation. Ecalectin induced concentration-dependent superoxide production from eosinophils but did not induce degranulation; usually these two events are coupled in eosinophil activation. Moreover, ecalectin directly prolonged eosinophil survival in vitro and did not trigger eosinophils to secrete cytokines that prolong eosinophil survival. These results demonstrate that ecalectin has several unique effects on eosinophils. Therefore, we conclude that ecalectin is a novel eosinophil-activating factor. Presumably, these effects allow ecalectin to play a distinctive role in allergic inflammation.

Original languageEnglish (US)
Pages (from-to)1961-1967
Number of pages7
JournalJournal of Immunology
Volume168
Issue number4
StatePublished - Feb 15 2002

Fingerprint

Eosinophils
Chemotactic Factors
eosinophil stimulating promoter
Galactosides
Galectins
Inflammation
Superoxides

ASJC Scopus subject areas

  • Immunology

Cite this

Matsumoto, R., Hirashima, M., Kita, H., & Gleich, G. J. (2002). Biological activities of ecalectin: A novel eosinophil-activating factor. Journal of Immunology, 168(4), 1961-1967.

Biological activities of ecalectin : A novel eosinophil-activating factor. / Matsumoto, Ryoji; Hirashima, Mitsuomi; Kita, Hirohito; Gleich, Gerald J.

In: Journal of Immunology, Vol. 168, No. 4, 15.02.2002, p. 1961-1967.

Research output: Contribution to journalArticle

Matsumoto, R, Hirashima, M, Kita, H & Gleich, GJ 2002, 'Biological activities of ecalectin: A novel eosinophil-activating factor', Journal of Immunology, vol. 168, no. 4, pp. 1961-1967.
Matsumoto R, Hirashima M, Kita H, Gleich GJ. Biological activities of ecalectin: A novel eosinophil-activating factor. Journal of Immunology. 2002 Feb 15;168(4):1961-1967.
Matsumoto, Ryoji ; Hirashima, Mitsuomi ; Kita, Hirohito ; Gleich, Gerald J. / Biological activities of ecalectin : A novel eosinophil-activating factor. In: Journal of Immunology. 2002 ; Vol. 168, No. 4. pp. 1961-1967.
@article{2a6410fc31244ee5b748460cd42596e7,
title = "Biological activities of ecalectin: A novel eosinophil-activating factor",
abstract = "Ecalectin, produced by Ag-stimulated T lymphocytes, is a potent eosinophil-specific chemoattractant in vitro as well as in vivo and thus is implicated in allergic responses. Ecalectin differs structurally from other known eosinophil chemoattractants (ECAs); ecalectin belongs to the galectin family defined by their affinity for β-galactosides and by their conserved carbohydrate recognition domains. These characteristic features suggest that ecalectin has unique activities associated with allergic inflammation besides ECA activity. Conversely, ecalectin may mediate ECA activity by binding to a receptor of a known ECA via affinity for the β-galactosides present on this receptor. In this study, we have tested whether ecalectin mediates ECA activity by binding to a receptor of a known ECA, and we have assessed its effects on eosinophils. Ecalectin did not mediate ECA activity by binding to the IL-5R or to CCR3. Also, the ECA activity of ecalectin was mainly chemokinetic. In addition, ecalectin induced concentration-dependent eosinophil aggregation, a marker for eosinophil activation. Ecalectin induced concentration-dependent superoxide production from eosinophils but did not induce degranulation; usually these two events are coupled in eosinophil activation. Moreover, ecalectin directly prolonged eosinophil survival in vitro and did not trigger eosinophils to secrete cytokines that prolong eosinophil survival. These results demonstrate that ecalectin has several unique effects on eosinophils. Therefore, we conclude that ecalectin is a novel eosinophil-activating factor. Presumably, these effects allow ecalectin to play a distinctive role in allergic inflammation.",
author = "Ryoji Matsumoto and Mitsuomi Hirashima and Hirohito Kita and Gleich, {Gerald J.}",
year = "2002",
month = "2",
day = "15",
language = "English (US)",
volume = "168",
pages = "1961--1967",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "4",

}

TY - JOUR

T1 - Biological activities of ecalectin

T2 - A novel eosinophil-activating factor

AU - Matsumoto, Ryoji

AU - Hirashima, Mitsuomi

AU - Kita, Hirohito

AU - Gleich, Gerald J.

PY - 2002/2/15

Y1 - 2002/2/15

N2 - Ecalectin, produced by Ag-stimulated T lymphocytes, is a potent eosinophil-specific chemoattractant in vitro as well as in vivo and thus is implicated in allergic responses. Ecalectin differs structurally from other known eosinophil chemoattractants (ECAs); ecalectin belongs to the galectin family defined by their affinity for β-galactosides and by their conserved carbohydrate recognition domains. These characteristic features suggest that ecalectin has unique activities associated with allergic inflammation besides ECA activity. Conversely, ecalectin may mediate ECA activity by binding to a receptor of a known ECA via affinity for the β-galactosides present on this receptor. In this study, we have tested whether ecalectin mediates ECA activity by binding to a receptor of a known ECA, and we have assessed its effects on eosinophils. Ecalectin did not mediate ECA activity by binding to the IL-5R or to CCR3. Also, the ECA activity of ecalectin was mainly chemokinetic. In addition, ecalectin induced concentration-dependent eosinophil aggregation, a marker for eosinophil activation. Ecalectin induced concentration-dependent superoxide production from eosinophils but did not induce degranulation; usually these two events are coupled in eosinophil activation. Moreover, ecalectin directly prolonged eosinophil survival in vitro and did not trigger eosinophils to secrete cytokines that prolong eosinophil survival. These results demonstrate that ecalectin has several unique effects on eosinophils. Therefore, we conclude that ecalectin is a novel eosinophil-activating factor. Presumably, these effects allow ecalectin to play a distinctive role in allergic inflammation.

AB - Ecalectin, produced by Ag-stimulated T lymphocytes, is a potent eosinophil-specific chemoattractant in vitro as well as in vivo and thus is implicated in allergic responses. Ecalectin differs structurally from other known eosinophil chemoattractants (ECAs); ecalectin belongs to the galectin family defined by their affinity for β-galactosides and by their conserved carbohydrate recognition domains. These characteristic features suggest that ecalectin has unique activities associated with allergic inflammation besides ECA activity. Conversely, ecalectin may mediate ECA activity by binding to a receptor of a known ECA via affinity for the β-galactosides present on this receptor. In this study, we have tested whether ecalectin mediates ECA activity by binding to a receptor of a known ECA, and we have assessed its effects on eosinophils. Ecalectin did not mediate ECA activity by binding to the IL-5R or to CCR3. Also, the ECA activity of ecalectin was mainly chemokinetic. In addition, ecalectin induced concentration-dependent eosinophil aggregation, a marker for eosinophil activation. Ecalectin induced concentration-dependent superoxide production from eosinophils but did not induce degranulation; usually these two events are coupled in eosinophil activation. Moreover, ecalectin directly prolonged eosinophil survival in vitro and did not trigger eosinophils to secrete cytokines that prolong eosinophil survival. These results demonstrate that ecalectin has several unique effects on eosinophils. Therefore, we conclude that ecalectin is a novel eosinophil-activating factor. Presumably, these effects allow ecalectin to play a distinctive role in allergic inflammation.

UR - http://www.scopus.com/inward/record.url?scp=0037083599&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037083599&partnerID=8YFLogxK

M3 - Article

C2 - 11823532

AN - SCOPUS:0037083599

VL - 168

SP - 1961

EP - 1967

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 4

ER -